Response to: Sequential therapy with antisense oligonucleotide and immune modulator as a strategy for HBV cure

IF 26.8 1区医学 Q1 GASTROENTEROLOGY & HEPATOLOGY Journal of Hepatology Pub Date : 2024-12-10 DOI:10.1016/j.jhep.2024.12.012

Maria Buti, Jeong Heo, Maximilian Lee

{"title":"Response to: Sequential therapy with antisense oligonucleotide and immune modulator as a strategy for HBV cure","authors":"Maria Buti, Jeong Heo, Maximilian Lee","doi":"10.1016/j.jhep.2024.12.012","DOIUrl":null,"url":null,"abstract":"<h2>Section snippets</h2><section><section><h2>Financial support</h2>GSK study 209348</section></section><section><section><h2>Authors’ contributions</h2>The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors, take responsibility for the integrity of the work as a whole, contributed to the writing and reviewing of the article, and have given final approval for the version to be published. Maria Buti and Jeong Heo contributed to the acquisition of data and data interpretation. Maximilian Lee contributed to the conception and design of the study, and the data analysis and interpretation.</section></section><section><section><h2>Declaration of Competing Interest</h2>MB has received grant support from Gilead and AbbVie, consultant fees from Gilead, AbbVie, Roche, Altimmune, and GSK, and lecture fees from Altimmune. JH has received grant support from Gilead and Roche, has received consultant fees from Roche, and lecture fees from AbbVie Korea, Roche, Yuhan Korea, Oncolys and Gilead, and is a member of an AstraZeneca steering committee. ML is an employee of and holds financial equities in GSK.</section></section>","PeriodicalId":15888,"journal":{"name":"Journal of Hepatology","volume":"20 1","pages":""},"PeriodicalIF":26.8000,"publicationDate":"2024-12-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jhep.2024.12.012","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Section snippets

Financial support

GSK study 209348

Authors’ contributions

The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors, take responsibility for the integrity of the work as a whole, contributed to the writing and reviewing of the article, and have given final approval for the version to be published. Maria Buti and Jeong Heo contributed to the acquisition of data and data interpretation. Maximilian Lee contributed to the conception and design of the study, and the data analysis and interpretation.

Declaration of Competing Interest

MB has received grant support from Gilead and AbbVie, consultant fees from Gilead, AbbVie, Roche, Altimmune, and GSK, and lecture fees from Altimmune. JH has received grant support from Gilead and Roche, has received consultant fees from Roche, and lecture fees from AbbVie Korea, Roche, Yuhan Korea, Oncolys and Gilead, and is a member of an AstraZeneca steering committee. ML is an employee of and holds financial equities in GSK.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

应答：以反义寡核苷酸和免疫调节剂序贯治疗HBV的策略

gsk研究209348作者的贡献作者符合国际医学期刊编辑委员会推荐的作者标准，对整个工作的完整性负责，对文章的写作和审稿做出了贡献，并最终批准了将要发表的版本。Maria Buti和Jeong Heo在数据采集和数据解释方面做出了贡献。Maximilian Lee对研究的构思和设计以及数据分析和解释做出了贡献。竞争利益声明mb获得了吉利德和艾伯维的资助，吉利德、艾伯维、罗氏、Altimmune和GSK的顾问费，以及Altimmune的讲学费。JH获得了吉利德和罗氏的资助支持，获得了罗氏的咨询费，以及艾伯维韩国、罗氏、Yuhan韩国、Oncolys和吉利德的演讲费，并且是阿斯利康指导委员会的成员。ML是GSK的雇员，并持有GSK的金融股权。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Journal of Hepatology 医学-胃肠肝病学

CiteScore

46.10

自引率

4.30%

发文量

2325

审稿时长

30 days

期刊介绍： The Journal of Hepatology is the official publication of the European Association for the Study of the Liver (EASL). It is dedicated to presenting clinical and basic research in the field of hepatology through original papers, reviews, case reports, and letters to the Editor. The Journal is published in English and may consider supplements that pass an editorial review.